Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | RBM39 | Q14498 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 8/20 | 0.47 |
| ▸ | HTT | P42858 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | MITF | O75030 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917021 | 0.87 | MAPT (0.44) | MAPTALDH1A1RBM39KMT2AKDM4E | |
| SCHEMBL914344 | 0.85 | MAPT (0.55) | MAPTALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL914944 | 0.85 | KMT2A (0.55) | MAPTALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL916652 | 0.84 | MAPT (0.44) | MAPTALDH1A1RBM39KMT2AKDM4E | |
| SCHEMBL916436 | 0.84 | MAPT (0.54) | MAPTKMT2AKDM4EGAAPOLB | |
| SCHEMBL915399 | 0.84 | CA1 (0.48) | MAPTALDH1A1KMT2AMEN1HTT | |
| SCHEMBL916513 | 0.83 | NCOA1 (0.49) | MAPTALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL915719 | 0.82 | MAPT (0.49) | MAPTALDH1A1RBM39KMT2AKDM4E | |
| SCHEMBL914941 | 0.82 | MAPT (0.51) | MAPTALDH1A1KMT2AGAAPOLB | |
| SCHEMBL916987 | 0.82 | MAPT (0.54) | MAPTALDH1A1RBM39KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | claimed |
| US-9227927-B2 | Method of treating inflammation | ANAMAR AB (SE) | 2016-01-05 | — | — | US | disclosed |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | disclosed |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | ANAMAR AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-8148429-B2 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ANAMAR AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110015437-A1 | USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2007-10-04 | — | — | US | disclosed |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MELACURE THERAPEUTICS AB (SE) | 2007-04-19 | — | — | US | disclosed |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | MAPT 4502/4885ALDH1A1 1879/4885RBM39 1315/4885 |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | MAPT 4496/4885ALDH1A1 1756/4885RBM39 1392/4885 |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | MAPT 4502/4885ALDH1A1 1879/4885RBM39 1315/4885 |
| US-20110015437-A1 | USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MC1R, MC5R, MCHR1 | MAPT 4502/4885ALDH1A1 1879/4885RBM39 1315/4885 |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | MC2R, MC5R, MC1R | MAPT 3465/4885ALDH1A1 1930/4885RBM39 2779/4885 |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | MC5R, MC1R, MC2R | MAPT 3995/4885ALDH1A1 2132/4885RBM39 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.